Mechanism for effective lymphoid cell and tissue loading following oral administration of nucleotide prodrug GS-7340

Molecular Pharmaceutics

Volumn 10, Issue 2, 2013, Pages 459-466

  Babusis, Darius ^a   Phan, Truc K ^a   Lee, William A ^a   Watkins, William J ^a   Ray, Adrian S ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

carboxylesterase; cathepsin A; hepatic extraction; intestinal absorption; P glycoprotein; prodrug; tenofovir

Indexed keywords

TENOFOVIR; TENOFOVIR ALAFENAMIDE; TENOFOVIR DIPHOSPHATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG EXPOSURE; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG PENETRATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG TRANSPORT; EXPERIMENTAL DOG; FIRST PASS EFFECT; HUMAN; HUMAN CELL; IN VITRO STUDY; LOADING DRUG DOSE; LOW DRUG DOSE; LYMPHOID CELL; LYMPHOID TISSUE; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; TARGET CELL;

ADENINE; ADMINISTRATION, ORAL; ANIMALS; CACO-2 CELLS; CATHEPSIN A; CHROMATOGRAPHY, LIQUID; DOGS; HUMANS; INTESTINAL ABSORPTION; LYMPHOCYTES; MALE; P-GLYCOPROTEIN; PRODRUGS; TANDEM MASS SPECTROMETRY;

EID: 84873394735     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp3002045     Document Type: Article

References (36)

1. Bhaskaran, K.; Hamouda, O.; Sannes, M.; Boufassa, F.; Johnson, A. M.; Lambert, P. C.; Porter, K. Changes in the risk of death after HIV seroconversion compared with mortality in the general population J. Am. Med. Assoc. 2008, 300 (1) 51-59 (Pubitemid 351920404)
2. Losina, E.; Schackman, B. R.; Sadownik, S. N.; Gebo, K. A.; Walensky, R. P.; Chiosi, J. J.; Weinstein, M. C.; Hicks, P. L.; Aaronson, W. H.; Moore, R. D.; Paltiel, A. D.; Freedberg, K. A. Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy Clin. Infect. Dis. 2009, 49 (10) 1570-1578
3. Nakagawa, F.; Lodwick, R. K.; Smith, C. J.; Smith, R.; Cambiano, V.; Lundgren, J. D.; Delpech, V.; Phillips, A. N. Projected life expectancy of people with HIV according to timing of diagnosis AIDS 2012, 26 (3) 335-343
4. El-Sadr, W. M.; Lundgren, J. D.; Neaton, J. D.; Gordin, F.; Abrams, D.; Arduino, R. C.; Babiker, A.; Burman, W.; Clumeck, N.; Cohen, C. J.; Cohn, D.; Cooper, D.; Darbyshire, J.; Emery, S.; Fatkenheuer, G.; Gazzard, B.; Grund, B.; Hoy, J.; Klingman, K.; Losso, M.; Markowitz, N.; Neuhaus, J.; Phillips, A.; Rappoport, C. CD4+ count-guided interruption of antiretroviral treatment N. Engl. J. Med. 2006, 355 (22) 2283-2296 (Pubitemid 44837777)
5. Friis-Moller, N.; Reiss, P.; Sabin, C. A.; Weber, R.; Monforte, A.; El-Sadr, W.; Thiebaut, R.; De Wit, S.; Kirk, O.; Fontas, E.; Law, M. G.; Phillips, A.; Lundgren, J. D. Class of antiretroviral drugs and the risk of myocardial infarction N. Engl. J. Med. 2007, 356 (17) 1723-1735 (Pubitemid 46658704)
6. Centers for Disease Control and Prevention. Behavioral Risk Factor Surveillance System. http://www.cdc.gov/brfss/index.htm (accessed March 12, 2012).
7. Centers forDisease Control and Prevention. Diagnoses of HIV Infection and AIDS in the United States and Dependent Areas, 2009. http://www.cdc.gov/hiv/ surveillance/resources/reports/2009report/index.htm (accessed March 12, 2012).
8. Thompson, M. A.; Aberg, J. A.; Cahn, P.; Montaner, J. S.; Rizzardini, G.; Telenti, A.; Gatell, J. M.; Gunthard, H. F.; Hammer, S. M.; Hirsch, M. S.; Jacobsen, D. M.; Reiss, P.; Richman, D. D.; Volberding, P. A.; Yeni, P.; Schooley, R. T. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel J. Am. Med. Assoc. 2010, 304 (3) 321-333
9. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2011. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (accessed April 10, 2012).
10. European AIDS Society. Guidlines for treatement of HIV infected adultsin Europe, 2011. http://www.europeanaidsclinicalsociety.org/index.php?option=com- content&view=article&id=59&Itemid=41 (accessed March 24, 2012).
11. Lee, W. A.; Martin, J. C. Perspectives on the development of acyclic nucleotide analogs as antiviral drugs Antiviral Res. 2006, 71 (2-3) 254-259 (Pubitemid 44223778)
12. Durand-Gasselin, L.; Van Rompay, K. K.; Vela, J. E.; Henne, I. N.; Lee, W. A.; Rhodes, G. R.; Ray, A. S. Nucleotide analogue prodrug tenofovir disoproxil enhances lymphoid cell loading following oral administration in monkeys Mol. Pharmaceutics 2009, 6 (4) 1145-1151
13. Lee, W. A.; He, G. X.; Eisenberg, E.; Cihlar, T.; Swaminathan, S.; Mulato, A.; Cundy, K. C. Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue Antimicrob. Agents Chemother. 2005, 49 (5) 1898-1906 (Pubitemid 40631605)
14. Birkus, G.; Wang, R.; Liu, X.; Kutty, N.; MacArthur, H.; Cihlar, T.; Gibbs, C.; Swaminathan, S.; Lee, W.; McDermott, M. Cathepsin A is the major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and GS-9131 Antimicrob. Agents Chemother. 2007, 51 (2) 543-550 (Pubitemid 46188294)
15. Markowitz, M.; Zolopa, A.; Ruane, P. J.; Squires, K.; Zhong, L.; Kearney, B. P.; Lee, W. GS-7340 Demonstrates Greater Declines in HIV-1 RNA than Tenofovir Disoproxil Fumarate During 14 Days of Monotherapy in HIV-1 Infected Subjects. 18th Conference on Retroviruses and Opportunistic Infections, Boston, MA, March 2, 2011.
16. Ruane, P. J.; Dejesus, E.; Berger, D.; Markowitz, N.; Bredeek, U. F.; Callebaut, C.; Zhong, L.; Ramanathan, S.; Rhee, M. S.; Yale, K. GS-7340 25 mg and 40 mg demonstrate superior efficacy to TDF 300 mg in a 10-day monotherapy study of HIV-1 infected patients. 19th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, March 7, 2012.
17. Rottier, R. J.; Hahn, C. N.; Mann, L. W.; del Pilar Martin, M.; Smeyne, R. J.; Suzuki, K.; d'Azzo, A. Lack of PPCA expression only partially coincides with lysosomal storage in galactosialidosis mice: indirect evidence for spatial requirement of the catalytic rather than the protective function of PPCA Hum. Mol. Genet. 1998, 7 (11) 1787-1794 (Pubitemid 28464154)
18. Birkus, G.; Kutty, N.; He, G. X.; Mulato, A.; Lee, W.; McDermott, M.; Cihlar, T. Activation of 9-[(R)-2-[[(S)-[[(S)-1-(Isopropoxycarbonyl)ethyl]amino] phenoxyphosphinyl]-methoxy]propyl]adenine (GS-7340) and other tenofovir phosphonoamidate prodrugs by human proteases Mol. Pharmacol. 2008, 74 (1) 92-100 (Pubitemid 351872162)
19. Obach, R. S.; Baxter, J. G.; Liston, T. E.; Silber, B. M.; Jones, B. C.; MacIntyre, F.; Rance, D. J.; Wastall, P. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data J. Pharmacol. Exp. Ther. 1997, 283 (1) 46-58 (Pubitemid 27438945)
20. Hidalgo, I. J.; Raub, T. J.; Borchardt, R. T. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability Gastroenterology 1989, 96 (3) 736-749 (Pubitemid 19057595)
21. Ray, A. S.; Cihlar, T.; Robinson, K. L.; Tong, L.; Vela, J. E.; Fuller, M. D.; Wieman, L. M.; Eisenberg, E. J.; Rhodes, G. R. Mechanism of active renal tubular efflux of tenofovir Antimicrob. Agents Chemother. 2006, 50 (10) 3297-3304 (Pubitemid 44527501)
22. National Research Council. Guide for the care and use of laboratory animals; National Academy Press: Washington, DC, 1996.
23. Vela, J. E.; Olson, L. Y.; Huang, A.; Fridland, A.; Ray, A. S. Simultaneous quantitation of the nucleotide analog adefovir, its phosphorylated anabolites and 2′-deoxyadenosine triphosphate by ion-pairing LC/MS/MS J. Chromatogr., B 2007, 848 (2) 335-343 (Pubitemid 46453307)
24. Chapman, E. H.; Kurec, A. S.; Davey, F. R. Cell volumes of normal and malignant mononuclear cells J. Clin. Pathol. 1981, 34 (10) 1083-1090 (Pubitemid 12239847)
25. Davies, B.; Morris, T. Physiological parameters in laboratory animals and humans Pharm. Res. 1993, 10 (7) 1093-1095 (Pubitemid 23211439)
26. Williams, E. T.; Bacon, J. A.; Bender, D. M.; Lowinger, J. J.; Guo, W. K.; Ehsani, M. E.; Wang, X.; Wang, H.; Qian, Y. W.; Ruterbories, K. J.; Wrighton, S. A.; Perkins, E. J. Characterization of the expression and activity of carboxylesterases 1 and 2 from the beagle dog, cynomolgus monkey, and human Drug Metab. Dispos. 2011, 39 (12) 2305-2313
27. Birkus, G.; Bam, R. A.; Frey, C. R.; Tsai, L.; Stray, K. M.; Yant, S. R.; Cihlar, T. Intracellular activation pathways for GS-7340 and the effect of antiviral protease inhibitors. 19th Conference on Retroviruses and Opportunistic Infections, Seattle, Washington, March 5-8, 2012.
28. Tong, L.; Phan, T. K.; Robinson, K. L.; Babusis, D.; Strab, R.; Bhoopathy, S.; Hidalgo, I. J.; Rhodes, G. R.; Ray, A. S. Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro Antimicrob. Agents Chemother. 2007, 51 (10) 3498-3504 (Pubitemid 47519335)
29. Raeissi, S. D.; Hidalgo, I. J.; Segura-Aguilar, J.; Artursson, P. Interplay between CYP3A-mediated metabolism and polarized efflux of terfenadine and its metabolites in intestinal epithelial Caco-2 (TC7) cell monolayers Pharm. Res. 1999, 16 (5) 625-632 (Pubitemid 29227089)
30. Wacher, V. J.; Wu, C. Y.; Benet, L. Z. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy Mol. Carcinog. 1995, 13 (3) 129-134
31. Garcia-Lerma, J. G.; Aung, W.; Cong, M. E.; Zheng, Q.; Youngpairoj, A. S.; Mitchell, J.; Holder, A.; Martin, A.; Kuklenyik, S.; Luo, W.; Lin, C. Y.; Hanson, D. L.; Kersh, E.; Pau, C. P.; Ray, A. S.; Rooney, J. F.; Lee, W. A.; Heneine, W. Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors J. Virol. 2011, 85 (13) 6610-6617
32. Pruvost, A.; Negredo, E.; Benech, H.; Theodoro, F.; Puig, J.; Grau, E.; Garcia, E.; Molto, J.; Grassi, J.; Clotet, B. Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients Antimicrob. Agents Chemother. 2005, 49 (5) 1907-1914 (Pubitemid 40631606)
33. Pruvost, A.; Negredo, E.; Theodoro, F.; Puig, J.; Levi, M.; Ayen, R.; Grassi, J.; Clotet, B. Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir Antimicrob. Agents Chemother. 2009, 53 (5) 1937-1943
34. Hawkins, T.; Veikley, W.; Durand-Gasselin, L.; Babusis, D.; Reddy, Y. S.; Flaherty, J. F.; Ray, A. S. Intracellular nucleotide levels during coadministration of tenofovir disoproxil fumarate and didanosine in HIV-1-infected patients Antimicrob. Agents Chemother. 2011, 55 (4) 1549-1555
35. Hawkins, T.; Veikley, W.; St Claire, R. L., 3rd; Guyer, B.; Clark, N.; Kearney, B. P. Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens J. Acquired Immune Defic. Syndr. 2005, 39 (4) 406-411 (Pubitemid 41003784)
36. Kiser, J. J.; Aquilante, C. L.; Anderson, P. L.; King, T. M.; Carten, M. L.; Fletcher, C. V. Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients J. Acquired Immune Defic. Syndr. 2008, 47 (3) 298-303 (Pubitemid 351619414)